Carna Newsletters are full of kinase-related information useful for your research!
If you wish to subscribe our newsletters, please apply here.
-
Apr 03, 2025
Vol.19 The involvement of extrachromosomal DNA (ecDNA) in intratumoral genetic heterogeneity and the potential of CHK1 inhibitors targeting ecDNA-containing tumors as next-generation cancer therapeutics
-
Nov 20, 2024
Vol.18 Clinical potential for off-target based drug repositioning
-
Jun 04, 2024
Vol.17 Development of targeted FGFR2 therapies in cholangiocarcinoma
-
Feb 22, 2024
Vol.16 Cancer treatments using inhibitors of CDK, a cell cycle regulator
-
Feb 22, 2023
Vol.15 ALK drug resistant mutations: Challenges for the treatment of lung cancer
-
Sep 06, 2022
Vol.14 DGKα and DGKζ are key targets for cancer immunotherapy
-
Jul 06, 2022
Vol.13 The potential of PIKfyve inhibitor as a treatment of amyotrophic lateral sclerosis (ALS)
-
Mar 02, 2022
Vol.12 The importance of understanding the activity of compounds on RAF dimerization in BRAF inhibitor drug discovery
-
Dec 09, 2021
Vol.11 Kinase Inhibitors as Potential Therapeutic Agents for COVID-19
-
May 26, 2021
Vol.10 Targeted Degradation of Non-catalytic Kinases
-
Feb 26, 2021
Vol.9 Drug-resistant EGFR mutations in lung cancer
-
Nov 27, 2020
Vol.8 Kinetic analysis of covalent and irreversible inhibitors
-
Apr 24, 2020
Vol.7 Kinase Inhibitors in the Fight against COVID-19
-
Mar 18, 2020
Vol.6 Recommendations for off-target profiling
-
Nov 27, 2019
Vol.5 Fragment-Based Drug Discovery
-
Oct 08, 2019
Vol.4 The significance of ATP concentration in cell-free and cell-based assays
-
Jul 30, 2019
Vol.3 Targeted Protein Degraders
-
Jun 25, 2019
Vol.2 Residence time and compound selectivity
-
Apr 16, 2019
Vol.1 A story about biotin-avidin affinity and how it accelerates small molecule drug discovery
Your comments on our newsletters and requests for a kinase related story you wish to hear are very much welcome!
